EUVIMEDSkopri EUVIMED
VergleichsstudieRandomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis

Alexandra Pyatt iD, Melissa McGowan, Ryota Tanaka iD, Bradley Miyagawa, Tomoyuki Mizuno iD, Adele Rike Shields iD, Annette Christianson, Patricia West-Thielke iD, John P Leone iD, E Steve Woodle iD, Dixon Kaufman iD, Alexander Wiseman iD and 3 more

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70172 ↗

At a glance

Vergleichsstudie in Clinical Transplantation, 2025. Written by Alexandra Pyatt and 14 co-authors. Institution: U Cincinnati, Cincinnati, Ohio, USA. Major MEDLINE topics: Immunosuppressive Agents, Graft Rejection, Kidney Transplantation, Abatacept. Cited 1 times so far (Crossref); 26 references. Funded by: Dialysis Clinics.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Belatacept (BELA) pharmacokinetic (PK) studies informed dosing strategies used in phase 3 studies, where fixed mg/kg dosing compared a less intensive (LI) and more intensive (MI) regimen. The LI regimen was preferred due to a better risk/benefit profile. We compared PK parameters observed in the BELA Early Steroid Withdrawal Trial (BEST) with previous reports. BELA trough samples were analyzed using a validated quantitative enzyme‐linked immunoassay. Clearance (CL) was estimated with Bayesian estimation using a published BELA population PK model. Significantly higher CL was observed in subjects

Subjects

MeSH terms (MEDLINE)

Immunosuppressive AgentsGraft RejectionKidney TransplantationAbataceptSteroidsKidney Failure, ChronicHumansMaleFemaleMiddle AgedPrognosisFollow-Up StudiesAdultGraft SurvivalGlomerular Filtration RateRisk FactorsAged

Substances

Immunosuppressive AgentsAbataceptSteroids

Authors and institutions

  • U Cincinnati, Cincinnati, Ohio, USA.
  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • UIC, Chicago, Illinois, USA.
  • Tampa General, Tampa, Florida, USA.
  • U Wisconsin, Madison, Wisconsin, USA.

ORCID profiles: Alexandra Pyatt, Ryota Tanaka, Tomoyuki Mizuno, Adele Rike Shields, Patricia West-Thielke, John P Leone, E Steve Woodle, Dixon Kaufman, Alexander Wiseman, Arthur J Matas, Alexander A Vinks, Rita R Alloway

Funding

  • Dialysis Clinics

Cite

APA

Pyatt, A., McGowan, M., Tanaka, R., Miyagawa, B., Mizuno, T., Shields, A. R., Christianson, A., West-Thielke, P., Leone, J. P., Woodle, E. S., Kaufman, D., Wiseman, A., Matas, A. J., Vinks, A. A., & Alloway, R. R. (2025). Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis. Clinical Transplantation. https://doi.org/10.1111/ctr.70172

Vancouver

Pyatt A, McGowan M, Tanaka R, Miyagawa B, Mizuno T, Shields AR, et al. Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis. Clinical Transplantation. 2025. doi:10.1111/ctr.70172

BibTeX
@article{Pyatt2025,
  author = {Pyatt, Alexandra and McGowan, Melissa and Tanaka, Ryota and Miyagawa, Bradley and Mizuno, Tomoyuki and Shields, Adele Rike and Christianson, Annette and West-Thielke, Patricia and Leone, John P and Woodle, E Steve and Kaufman, Dixon and Wiseman, Alexander and Matas, Arthur J and Vinks, Alexander A and Alloway, Rita R},
  title = {Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70172}
}
Start for free →